caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1306861950

Thomas KippsM.D.

Hematology-OncologyLa Jolla, CAI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
FACILITY AFFILIATIONS

Hospital & Facility Affiliations (2)

CCN 050025
Hospital
CCN 050351
Hospital
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
172
Unique beneficiaries
—
Total services
344
Distinct HCPCS
1
Medicare payment
$37K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 957 Hematology-Oncology providers in CA — bottom quintile (cohort median 4,173).
REFERRAL NETWORK

Where Thomas Kipps's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 4 inbound referrers · 6 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
REGENTS OF THE UNIVERSITY OF CALIFORNIA1592,569
MCALPIN, REBECCA36195
BROOME, HELEN24117
Unilab Corporation
Clinical Laboratory · West Hills, CA
1351
Refers patients to
Outbound — where patients go next
PhysicianPatientsVisits
REGENTS OF THE UNIVERSITY OF CALIFORNIA831,072
Michael Choi
Hematology-Oncology · San Diego, CA
35301
Huan-You Wang
Pathology · San Diego, CA
24137
MCALPIN, REBECCA22114
Laboratory Corporation Of America
Clinical Laboratory · San Diego, CA
1388
BROOME, HELEN1152
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
PRESCRIBING · PART D · 2024
Total Rx claims
770
Beneficiaries
—
Total drug cost
$7.5M
Distinct drugs
16
Brand share
76.0%
Top prescribed drugs
Ibrutinib156 claims
Acyclovir107 claims
Zanubrutinib100 claims
Acalabrutinib Maleate97 claims
Pirtobrutinib52 claims
QUALITY · MIPS · 2024
Final MIPS score
90.8
Quality
84.1
Cost
73.9
Improvement activities
40.0
Promoting interop.
100.0
Payment adjustment
0.66%
Group
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
Total received
$6K
Payment records
18
By payment type
Consulting Fee$4K
Travel and Lodging$2K
Food and Beverage$425
Education$30